Results 201 to 210 of about 5,478,695 (241)

Interleukin‐12: Central Roles in Immune Regulation and Disease Therapy

Immunology &Cell Biology, Volume 104, Issue 10, Page 996-1014, November‐December 2026.
IL‐12 levels are tightly regulated to balance effective protective immunity against infections and cancer with the risk of excessive inflammation and autoimmune disease. Both insufficient and excessive IL‐12 activity can therefore be detrimental, highlighting the importance of precisely controlling its production and signaling. ABSTRACT Interleukin‐12 (
Anthi Psoma, Geert van den Bogaart
wiley   +1 more source

The Cytokine Response of Circulating Immune Cells to Rhinovirus (RV‐A16) is Reduced in Severe Asthma

Journal of Cellular and Molecular Medicine, Volume 30, Issue 21, November 2026.
ABSTRACT Severe asthma patients (SA) are more susceptible to respiratory infections with human rhinoviruses (HRV) than healthy subjects (H), causing exacerbations. In response to HRV, circulating immune cells are recruited to and activated at the local sites of infection.
Kaschin Jamal Jameel, Sarah D. Yanik, Kai Robin Pfeifer, Daniel Weidinger, Simon Rohde, Birte Struck, Eike Bülthoff, Paul Bürger, Juliane Kronsbein, Matthias Tenbusch, Jürgen Knobloch   +10 more
wiley   +1 more source

An Australian Narrative Review of Adoptive Cellular Therapies in Malignancy: Expanding Indications, Referral Pathways and Safety Beyond Specialist Centres

Medical Journal of Australia, Volume 224, Issue 11, November 2026.
ABSTRACT Adoptive cellular therapies (ACT), including tumour‐infiltrating lymphocyte (TIL), T‐cell receptor‐engineered T (TCR‐T) cell and chimeric antigen receptor T‐cell (CAR‐T) therapies, represent an evolving class of immunotherapies with established efficacy in selected haematological malignancies and emerging applications in solid tumours ...
Sarah Childs, David Ma, Anthony Rodrigues, Jennifer Massey, Rasha Cosman, Venessa Chin, Laila Girgis, James Lynam, Peter Lau, Barbara Withers, Anthony M. Joshua, Ben Tran, Jayesh Desai, Simon J. Harrison, John Moore, Jia Liu   +15 more
wiley   +1 more source

Encoding Cell‐Surface Receptor Function Through Glycosylation: Lessons From CD44

ChemBioChem, Volume 27, Issue 19, 14 October 2026.
CD44 function is not solely determined by its protein sequence, it is dynamically encoded by its glycosylation state. Glycan remodeling generates distinct functional receptor states that regulate ligand recognition, receptor organization, lectin interactions, and signaling.
María Payá‐García, José Manuel Rojas‐Marcos, Iris A. Bermejo, Diego Del Balzo, Ana Ardá, Luca Unione, Jesús Jiménez‐Barbero, Ana Gimeno   +7 more
wiley   +1 more source

Coinfections With Respiratory Syncytial Virus in a Cohort of Adults With High‐Risk Conditions, 2015–2020: A Retrospective Observational Study

Health Science Reports, Volume 9, Issue 11, November 2026.
Oluwakemi D. Alonge, Maria E. Sundaram, Huong Q. Nguyen, Jennifer P. King, Elisha Stefanski, Andrew G. Allmon, Jean‐Yves Pirçon, Pouya Saeedi   +7 more
wiley   +1 more source

Abstract Supplement HIV Glasgow 8–11 November 2026, Glasgow, UK/Virtual

Journal of the International AIDS Society, Volume 29, Issue S6, November 2026.
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

CAR-NK cells: a promising cellular immunotherapy in lymphoma

Expert Opinion on Biological Therapy, 2022
New methods in cancer immunotherapy, such as chimeric antigen receptor (CAR)-T cells, have shown promising results in destroying malignant cells. However, limitations and side effects of CAR-T cell therapy, such as graft-versus-host disease (GVHD), neurotoxicity, and cytokine release syndrome, have motivated researchers to investigate safer alternative
Shaghayegh, Khanmohammadi, Nima, Rezaei
openaire   +2 more sources

CAR-NK cells for haematological cancers

Best Practice & Research Clinical Haematology
Chimeric antigen receptor-natural-killer (CAR-NK)-cells are a promising cancer cell therapy. Several features of CAR-NK-cells are suggesting an advantage over CAR-T-cells such as less complex manufacturing, "off-the-shelf" use and lower risks of cytokine release (CRS) and immune effector cell-associated neurotoxicity syndromes (ICANS).
Mohammadamin Noorafrooz, Robert Peter Gale, Ramin Noorafrooz, Sanaz Ghods   +3 more
openaire   +2 more sources

CAR‐NK cell‐based therapies: translational and regulatory breakthroughs

Immunology & Cell Biology
In this article for the "Highlights of 2025" series, we discuss advances in chimeric antigen receptor (CAR)-engineered natural killer (NK) cell therapies. We highlight iPSC-derived manufacturing, expansion into autoimmune disease, discovery of intrinsic regulators, and rational antigen targeting, illustrating how discovery-driven biology and ...
Alison Felipe Bordini Biggi, Fernando Souza‐Fonseca‐Guimaraes   +1 more
openaire   +3 more sources

CAR-NK Cell: A New Paradigm in Tumor Immunotherapy

2021
البيئة الدقيقة للورم (TME) متعددة الأوجه إلى حد كبير والهروب المناعي هو سمة حتمية للأورام التي تعزز تطور الورم والانبثاث. بناءً على التقارير، يعكس الإنجاز المقيد الذي حققه العلاج المناعي بالخلايا التائية أهمية العلاجات المناعية المبتكرة الأخرى الناشئة، ولا سيما العلاجات القائمة على الخلايا القاتلة الطبيعية (NK).
Faroogh Marofi, Alaa Sadeq Al-Awad, Heshu Sulaiman Rahman, Walid Kamal Abdelbasset, Yulianna Enina, Mahnaz Mahmoodi, Ali Hassanzadeh, Mahboubeh Yazdanifar, Max Stanley Chartrand, Mostafa Jarahian   +9 more
openaire   +1 more source